Altogether, these results strongly support the hypothesis that mKRAS epitopes are processed and presented by tumor cells in the context of HLA-A*03:01, HLA-A*11:01 and HLA-B*07:02 at sufficient levels to activate recognition by mKRAS-TCR-engineered T cells. Here, HLA-A is linked to neoplasm.